A novel CMKLR1 small molecule antagonist suppresses CNS autoimmune inflammatory disease

PLoS ONE

Volumn 9, Issue 12, 2014, Pages

  Graham, Kareem L ^a,d   Zhang, Jian V ^a,e   Lewén, Susanna ^a   Burke, Thomas M ^a   Dang, Ton ^b   Zoudilova, Maria ^c,f   Sobel, Raymond A ^c   Butcher, Eugene C ^c   Zabel, Brian A ^a  

^a VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^b ChemoCentryx Inc   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e INSTITUTE OF GEOLOGY AND GEOPHYSICS   (China)

^f GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (ALPHA NAPHTHOYL) ETHYLTRIMETHYLAMMONIUM IODIDE; BETA ARRESTIN 2; CHEMERIN; CHEMOKINE LIKE RECEPTOR 1 INHIBITOR; CHEMOTAXIS AFFECTING AGENT; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; UNCLASSIFIED DRUG; 2-NAPHTHOYLETHYLTRIMETHYLAMMONIUM; BETA ARRESTIN; CHEMERIN PROTEIN, MOUSE; CHEMOKINE; CMKLR1 PROTEIN, MOUSE; G PROTEIN COUPLED RECEPTOR; NAPHTHALENE DERIVATIVE; QUATERNARY AMMONIUM DERIVATIVE; RETINA S ANTIGEN; SIGNAL PEPTIDE;

ACTIVE IMMUNIZATION; ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ASSAY; CELL INFILTRATION; CELL MIGRATION; CELL PROLIFERATION ASSAY; CHEMOTAXIS ASSAY; DISEASE MODEL; DRUG SCREENING; DRUG STABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; FEMALE; FLOW CYTOMETRY; HISTOPATHOLOGY; MONONUCLEAR CELL; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; SINGLE BLIND PROCEDURE; T LYMPHOCYTE; ANIMAL; ANTAGONISTS AND INHIBITORS; BRAIN; C57BL MOUSE; CELL MOTION; CHEMISTRY; DRUG EFFECTS; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; HUMAN; IMMUNOLOGY; LEUKOCYTE; METABOLISM; PATHOLOGY; SAFETY; SPINAL CORD; STRUCTURE ACTIVITY RELATION;

ANIMALIA; MUS;

ANIMALS; ARRESTINS; BRAIN; CELL MOVEMENT; CHEMOKINES; DRUG EVALUATION, PRECLINICAL; DRUG STABILITY; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LEUKOCYTES; MICE; MICE, INBRED C57BL; NAPHTHALENES; QUATERNARY AMMONIUM COMPOUNDS; RECEPTORS, G-PROTEIN-COUPLED; SAFETY; SPINAL CORD; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84918837762     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0112925     Document Type: Article

References (59)

1. Steinman L (2001) Multiple sclerosis: a two-stage disease. Nat Immunol 2: 762-764.
2. Kleinschmidt-DeMasters BK, Tyler KL (2005) Progressive Multifocal Leukoencephalopathy Complicating Treatment with Natalizumab and Interferon Beta-1a for Multiple Sclerosis. New England Journal of Medicine 353: 369-374.
3. Langer-Gould A, Atlas SW, Green AJ, Bollen AW, Pelletier D (2005) Progressive Multifocal Leukoencephalopathy in a Patient Treated with Natalizumab. New England Journal of Medicine 353: 375-381.
4. Linda˚ H, von Heijne A, Major EO, Ryschkewitsch C, Berg J, et al. (2009) Progressive Multifocal Leukoencephalopathy after Natalizumab Monotherapy. New England Journal of Medicine 361: 1081-1087.
5. Mullen J, Vartanian T, Atkins M (2008) Melanoma complicating treatment with natalizumab for multiple sclerosis. The New England Journal of Medicine 358: 647-648.
6. Cohen JA, Barkhof F, Comi G, Hartung H-P, Khatri BO, et al. (2010) Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis. New England Journal of Medicine 362: 402-415.
7. Kappos L, Radue E-W, O'Connor P, Polman C, Hohlfeld R, et al. (2010) A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis. New England Journal of Medicine 362: 387-401.
8. Wittamer V, Franssen JD, Vulcano M, Mirjolet JF, Le Poul E, et al. (2003) Specific Recruitment of Antigen-presenting Cells by Chemerin, a Novel Processed Ligand from Human Inflammatory Fluids. Journal of Experimental Medicine 198: 977-985.
9. Zabel BA, Silverio AM, Butcher EC (2005) Chemokine-Like Receptor 1 Expression and Chemerin-Directed Chemotaxis Distinguish Plasmacytoid from Myeloid Dendritic Cells in Human Blood. The Journal of Immunology 174: 244-251.
10. Zabel BA, Ohyama T, Zuniga L, Kim JY, Johnston B, et al. (2006) Chemokine-like receptor 1 expression by macrophages in vivo: regulation by TGF-beta and TLR ligands. Experimental Hematology 34: 1106-1114.
11. Parolini S, Santoro A, Marcenaro E, Luini W, Massardi L, et al. (2007) The role of chemerin in the colocalization of NK and dendritic cell subsets into inflamed tissues. Blood 109: 3625-3632.
12. Graham KL, Zabel BA, Loghavi S, Zuniga LA, Ho PP, et al. (2009) Chemokine-like receptor-1 expression by central nervous system-infiltrating leukocytes and involvement in a model of autoimmune demyelinating disease. The Journal of Immunology 183: 6717-6723.
13. Lande R, Gafa V, Serafini B, Giacomini E, Visconti A, et al. (2008) Plasmacytoid dendritic cells in multiple sclerosis: Intracerebral recruitment and impaired maturation response to interferon-b. J Neuropathol Exp Neurol 67: 388-401.
14. Zabel BA, Nakae S, Zuniga L, Kim JY, Ohyama T, et al. (2008) Mast cell-expressed orphan receptor CCRL2 binds chemerin and is required for optimal induction of IgE-mediated passive cutaneous anaphylaxis. J Exp Med 205: 2207-2220.
15. Zabel BA, Allen SJ, Kulig P, Allen JA, Cichy J, et al. (2005) Chemerin activation by serine proteases of the coagulation, fibrinolytic, and inflammatory cascades. The Journal of biological chemistry 280: 34661-34666.
16. Shenoy SK, Lefkowitz RJ (2003) Multifaceted roles of beta-arrestins in the regulation of seven-membrane-spanning receptor trafficking and signalling. Biochemical Journal 375: 503-515.
17. Zabel BA, Nakae S, Zuniga L, Kim JY, Ohyama T, et al. (2008) Mast cell-expressed orphan receptor CCRL2 binds chemerin and is required for optimal induction of IgE-mediated passive cutaneous anaphylaxis. Journal of Experimental Medicine 205: 2207-2220.
18. Sastry BV, Jaiswal N, Owens LK, Janson VE, Moore RD (1988) 2-(alpha-Naphthoyl) ethyltrimethylammonium iodide and its beta-isomer: new selective, stable and fluorescent inhibitors of choline acetyltransferase. Journal of Pharmacology and Experimental Therapeutics 245: 72-80.
19. Sastry BV, Jaiswal N, Janson V, Day PS, Naukam RJ (1988) Relationships between chemical structure and inhibition of choline acetyltransferase by 2-(alpha-naphthoyl)ethyltrimethylammonium and related compounds. Pharmacol Res Commun 20: 751-771.
20. PubChem (2014) National Center for Biotechnology Information PubChem Compound Database; CID=11957648, https://pubchemncbinlmnihgov/summary/summarycgi?cid=11957648 (accessed Feb 22, 2014).
21. PubChem (2014) National Center for Biotechnology Information PubChem Compound Database; CID=1518, https://pubchemncbinlmnihgov/summary/summarycgi?cid=1518 (accessed Feb 22, 2014).
22. PubChem (2011) National Center for Biotechnology Information PubChem BioAssay Database; AID=493210, Source=NIH/NCGC, https://pubchemncbinlmnihgov/assay/assaycgi?aid=493210 (accessed Feb 22, 2014).
23. PubChem (2011) National Center for Biotechnology Information PubChem BioAssay Database; AID=504332, Source=NIH/NCGC, https://pubchemncbinlmnihgov/assay/assaycgi?aid=504332 (accessed Feb 22, 2014).
24. PubChem (2008) National Center for Biotechnology Information PubChem BioAssay Database; AID=1461, Source=NIH/NCGC, https://pubchemncbinlmnihgov/assay/assaycgi?aid=1461 (accessed Feb 22, 2014).
25. PubChem (2007) National Center for Biotechnology Information PubChem BioAssay Database; AID=943, Source=NIH/NCGC, https://pubchemncbinlmnihgov/assay/assaycgi?aid=943 (accessed Feb 22, 2014).
26. PubChem (2008) National Center for Biotechnology Information PubChem BioAssay Database; AID51422, Source5Emory University Molecular Libraries Screening Center, https://pubchemncbinlmnihgov/assay/assaycgi?aid=1422 (accessed Feb 22, 2014).
27. Wittamer V, Franssen J-D, Vulcano M, Mirjolet J-F, Le Poul E, et al. (2003) Specific recruitment of antigen-presenting cells by chemerin, a novel processed ligand from human inflammatory fluids. Journal of Experimental Medicine 198: 977-985.
28. Cruz-Orengo L, Chen YJ, Kim JH, Dorsey D, Song SK, et al. (2011) CXCR7 antagonism prevents axonal injury during experimental autoimmune encephalomyelitis as revealed by in vivo axial diffusivity. J Neuroinflammation 8: 170.
29. Sanguinetti MC, Jiang C, Curran ME, Keating MT (1995) A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel. Cell 81: 299-307.
30. Redfern WS, Wakefield ID, Prior H, Pollard CE, Hammond TG, et al. (2002) Safety pharmacology - a progressive approach. Fundam Clin Pharmacol 16: 161-173.
31. PubChem (2011) National Center for Biotechnology Information PubChem BioAssay Database; AID=588834, Source=NIH/NCGC, https://pubchemncbinlmnihgov/assay/assaycgi?aid=588834 (accessed Feb 22, 2014).
32. Springer C, Sokolnicki KL (2013) A fingerprint pair analysis of hERG inhibition data. Chem Cent J 7: 167.
33. Lynch T, Price A (2007) The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects. Am Fam Physician 76: 391-396.
34. PubChem (2009) National Center for Biotechnology Information PubChem BioAssay Database; AID=1851, Source=NIH/NCGC, https://pubchemncbinlmnihgov/assay/assaycgi?aid=1851 (accessed Feb 22, 2014).
35. Obach RS, Walsky RL, Venkatakrishnan K, Gaman EA, Houston JB, et al. (2006) The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions. J Pharmacol Exp Ther 316: 336-348.
36. Horn JR, Hansten PD (2008) Get to Know and Enzyme: CYP3A4. Pharmacy Times 0: 40-43.
37. Charo IF, Ransohoff RM (2006) The Many Roles of Chemokines and Chemokine Receptors in Inflammation. The New England Journal of Medicine 354: 610-621.
38. Monnier J, Lewen S, O'Hara E, Huang K, Tu H, et al. (2012) Expression, regulation, and function of atypical chemerin receptor CCRL2 on endothelial cells. J Immunol 189: 956-967.
39. von Degenfeld G, Wehrman TS, Hammer MM, Blau HM (2007) A universal technology for monitoring G-protein-coupled receptor activation in vitro and noninvasively in live animals. The FASEB Journal 21: 3819-3826.
40. Racke MK, Burnett D, Pak SH, Albert PS, Cannella B, et al. (1995) Retinoid treatment of experimental allergic encephalomyelitis. IL-4 production correlates with improved disease course. J Immunol 154: 450-458.
41. Winkler-Pickett R, Young HA, Cherry JM, Diehl J, Wine J, et al. (2008) In vivo regulation of experimental autoimmune encephalomyelitis by NK cells: alteration of primary adaptive responses. J Immunol 180: 4495-4506.
42. Schall TJ, Proudfoot AE (2011) Overcoming hurdles in developing successful drugs targeting chemokine receptors. Nature reviews Immunology 11: 355-363.
43. Pardridge WM (2005) The blood-brain barrier: Bottleneck in brain drug development. Neurotherapeutics 2: 3-14.
44. Banks WA (2009) Characteristics of compounds that cross the blood-brain barrier. BMC neurology 9 Suppl 1: S3.
45. Polman CH, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, et al. (2006) A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis. New England Journal of Medicine 354: 899-910.
46. Rudick RA, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, et al. (2006) Natalizumab plus Interferon Beta-1a for Relapsing Multiple Sclerosis. New England Journal of Medicine 354: 911-923.
47. Mandala S, Hajdu R, Bergstrom J, Quackenbush E, Xie J, et al. (2002) Alteration of Lymphocyte Trafficking by Sphingosine-1-Phosphate Receptor Agonists. Science 296: 346-349.
48. Kappos L, Antel J, Comi G, Montalban X, O'Connor P, et al. (2006) Oral Fingolimod (FTY720) for Relapsing Multiple Sclerosis. New England Journal of Medicine 355: 1124-1140.
49. Bondue B, Vosters O, de Nadai P, Glineur Sp, De Henau O, et al. (2011) ChemR23 Dampens Lung Inflammation and Enhances Anti-viral Immunity in a Mouse Model of Acute Viral Pneumonia. PLoS Pathog 7: e1002358.
50. Luangsay S, Wittamer V, Bondue B, De Henau O, Rouger L, et al. (2009) Mouse ChemR23 is expressed in dendritic cell subsets and macrophages, and mediates an anti-inflammatory activity of chemerin in a lung disease model. J Immunol 183: 6489-6499.
51. Demoor T, Bracke KR, Dupont LL, Plantinga M, Bondue B, et al. (2011) The Role of ChemR23 in the Induction and Resolution of Cigarette Smoke-Induced Inflammation. The Journal of Immunology 186: 5457-5467.
52. Cash JL, Hart R, Russ A, Dixon JPC, Colledge WH, et al. (2008) Synthetic chemerin-derived peptides suppress inflammation through ChemR23. Journal of Experimental Medicine 205: 767-775.
53. Ernst MC, Haidl ID, Z√D√±iga LA, Dranse HJ, Rourke JL, et al. (2012) Disruption of the Chemokine-Like Receptor-1 (CMKLR1) Gene Is Associated with Reduced Adiposity and Glucose Intolerance. Endocrinology 153: 672-682.
54. Issa ME, Muruganandan S, Ernst MC, Parlee SD, Zabel BA, et al. (2012) Chemokine-like receptor 1 regulates skeletal muscle cell myogenesis. American Journal of Physiology - Cell Physiology 302: C1621-C1631.
55. Venci JV, Gandhi MA (2013) Dimethyl fumarate (Tecfidera): a new oral agent for multiple sclerosis. Ann Pharmacother 47: 1697-1702.
56. Schilling S, Goelz S, Linker R, Luehder F, Gold R (2006) Fumaric acid esters are effective in chronic experimental autoimmune encephalomyelitis and suppress macrophage infiltration. Clin Exp Immunol 145: 101-107.
57. Horuk R (2009) Chemokine receptor antagonists: overcoming developmental hurdles. Nature Reviews Drug Discovery 8: 23-33.
58. Overington J, Al-Lazikani B, Hopkins A (2006) How many drug targets are there? Nature Reviews Drug Discovery 5: 993-996.
59. Walters MJ, Wang Y, Lai N, Baumgart T, Zhao BN, et al. (2010) Characterization of CCX282-B, an Orally Bioavailable Antagonist of the CCR9 Chemokine Receptor, for Treatment of Inflammatory Bowel Disease. Journal of Pharmacology and Experimental Therapeutics 335: 61-69.